Published on 2 Mar 2024 on Simply Wall St. via Yahoo Finance

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue...

Today is shaping up negative for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

Following the latest downgrade, the four analysts covering Arbutus Biopharma provided consensus estimates of US$8.3m revenue in 2024, which would reflect a painful 54% decline on its sales over the past 12 months. Per-share losses are expected to creep up to US$0.46. Yet before this consensus update, the analysts had been forecasting revenues of US$15m and losses of US$0.43 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

View our latest analysis for Arbutus Biopharma